Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome

This study has been withdrawn prior to enrollment.
(Study withdrawn due to budget (personnel) limitations.)
Sponsor:
Information provided by:
University of South Florida
ClinicalTrials.gov Identifier:
NCT00584246
First received: December 21, 2007
Last updated: June 2, 2008
Last verified: June 2008
  Purpose

This study will evaluate the safety and efficacy of Pregabalin (Lyrica) in treating patients with Restless Legs Syndrome (RLS) in a double-blind, placebo-controlled trial.


Condition Intervention Phase
Restless Legs Syndrome
Drug: Pregabalin (Lyrica)
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome

Resource links provided by NLM:


Further study details as provided by University of South Florida:

Primary Outcome Measures:
  • International RLS Study Group Severity Scale (IRLS) [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical Global Impression (CGI) [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 22
Study Start Date: November 2007
Estimated Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Pregabalin (Lyrica)
Drug: Pregabalin (Lyrica)
50 - 150 mg po qhs for 2 months
Placebo Comparator: 2
Placebo
Drug: Pregabalin (Lyrica)
50 - 150 mg po qhs for 2 months
Drug: Placebo
50 - 150 mg po qhs for 2 months

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Outpatients with RLS diagnosed by a movement disorder specialist/ Sleep specialist .
  2. Patients must report some degree of pain which occurs on a regular basis.
  3. Age 18 years to 80 years.
  4. Women of child-bearing potential must use a reliable method of contraception and must provide a negative pregnancy test at entry into the study.
  5. Stable doses of all medications for 30 days prior to study entry and for the duration of the study.
  6. Willing and able to provide informed consent.
  7. Willing to comply with protocol. -

Exclusion Criteria:

  1. Any illness that in the investigator's opinion preclude participation in this study.
  2. Pregnancy or lactation.
  3. Concurrent participation in another clinical study.
  4. Current treatment with a dopamine agonist (unless stopped at least 2 weeks prior to baseline).
  5. Dementia or other psychiatric illness that prevents the patient from giving informed consent (Mini Mental Status Exam score less than 24).
  6. Legal incapacity or limited legal capacity.
  7. Presence of severe renal disease BUN 50% greater than normal, Patients must have evidence from their PCP or Urologists of normal PSA and urodynamic tests within the last 12 month. Normal BUN levels should be within a range of 5 to 20 mg/ d L and creatinine between .7 and 1.4 mg/ d L. Labs will be requested from PCP.
  8. Presence of major hepatic impairment (Cirrhosis, Viral Hepatitis, Nonalcoholic Steatohepatitis, Wilson's disease, or Hemochromatosis). LFT must show non-clinically significant results (Albumin range 3.0-6.0; Alkaline phosphatase range 40-150; ALT range 0-55; AST range 5-34).
  9. Presence of severe daytime sleepiness.
  10. Present complaints of somnolence, dizziness, blurred vision, bleeding tendencies, cardiac abnormalities.
  11. Patients taking dopamine agonists for any condition other than RLS. -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00584246

Locations
United States, Florida
University of South Florida
Tampa, Florida, United States, 33612
Sponsors and Collaborators
University of South Florida
Investigators
Principal Investigator: Theresa A Zesiewicz, MD University of South Florida
  More Information

No publications provided

Responsible Party: Theresa Zesiewicz, MD, University of South Florida
ClinicalTrials.gov Identifier: NCT00584246     History of Changes
Other Study ID Numbers: 3, 105362
Study First Received: December 21, 2007
Last Updated: June 2, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by University of South Florida:
Restless legs syndrome
RLS
Pregabalin
Lyrica

Additional relevant MeSH terms:
Syndrome
Psychomotor Agitation
Restless Legs Syndrome
Disease
Pathologic Processes
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Parasomnias
Mental Disorders
Pregabalin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on September 18, 2014